CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 350 enrolled
Drug / intervention
ABT-981 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02087904
NCT02087904Phase 2Completed

A Phase 2a Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis

AbbVie·interventional·Posted Mar 14, 2014·Updated Aug 28, 2019

In Brief

A Phase 2 clinical trial evaluating ABT-981 and Placebo for Knee Osteoarthritis and Medial Compartment Knee Osteoarthritis. Completed, enrolled 350 participants.

Detailed Summary

A Phase 2a, multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the safety, tolerability, efficacy and pharmacokinetic/pharmacodynamic effect of ABT-981 in patients with symptomatic, radiographic, and inflammatory knee osteoarthritis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 14, 2014
Enrollment StartJun 4, 2014
Primary CompletionJun 7, 2016
Study CompletionDec 13, 2016
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 12.3 years ago

Interventions

ABT-981biological

Placeboother